查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1355208

化疗市场 - 2018-2028F 全球产业规模、份额、趋势、机会和预测，按类型、适应症、剂型、给药途径、最终用户、地区和竞争细分

Chemotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Type, By Indication, By Dosage Form, By Route of Administration, By End User, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 190 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022 年全球化疗市场价值为 82.6 亿美元，预计在预测期内将强劲增长，到 2028 年复合年增长率为 8.51%。世界卫生组织 (WHO) 指出，癌症是第二大原因全球死亡率增加，预计2018 年有960 万人死亡。鑑于癌症发生率不断上升，对化疗药物的需求将会增加。化疗是一种癌症治疗方法，利用强效化学物质瞄准并消除体内快速分裂的细胞。它已被证明可以有效减少癌细胞数量、阻止癌症进展和缩小肿瘤。

化疗通常是单独或合併使用，是治疗多种癌症的一般治疗方式。它作为主要或唯一的治疗方法，消除隐藏的癌细胞并为患者准备其他干预措施，例如放射或手术。此外，它还可以透过选择性地靶向癌细胞来减轻与癌症相关的体征和症状。

主要市场驱动因素

市场概况
预测期 2024-2028
2022 年市场规模 82.6亿美元
2028 年市场规模 133.9亿美元
2023-2028 年复合年增长率 8.51%
成长最快的细分市场 烷基化剂
最大的市场 北美洲

癌症发生率上升

癌症盛行率的增加预计将推动化疗药物市场的成长。根据世界卫生组织 (WHO) 的数据，癌症是全球死亡的主要原因，2020 年约有 1,000 万人因癌症死亡，即近六分之一的死亡。每年，大约有 40 万名儿童接受癌症诊断。子宫颈癌是全球 23 个国家最常见的癌症。化疗通常与其他癌症治疗结合使用，仍然是癌症治疗的主要方法。新辅助化疗是指在手术前进行化疗和放射治疗以缩小肿瘤大小，而辅助化疗是在手术或放射治疗后进行以进一步缩小肿瘤。

增加医疗基础建设投资

影响化疗药物市场成长率的另一个重要因素是医疗保健支出的增加，这有助于其基础设施的改善。此外，各政府组织致力于透过增加资金来加强医疗基础设施，进而影响市场动态。增加的投资可以建立和扩大专门的癌症治疗中心，配备最先进的化疗管理、监测和支持护理设施。医疗保健基础设施投资确保患者能够接触到肿瘤学家、血液学家、病理学家、放射科医生和其他在规划和提供化疗治疗中发挥关键作用的专家。设备齐全的医疗设施可以透过先进的影像技术、活检和分子检测提供准确、及时的癌症诊断，指导选择合适的化疗方案。充足的基础设施支持临床试验的进行，使患者能够获得创新的化疗治疗，并有助于开发新的治疗方案。此外，老年人口的扩大和对先进抗癌药物不断增长的需求将推动化疗药物市场的扩大。此外，人们对化疗的认识不断增强，加上接受化疗和放疗的患者数量不断增加，预计将促进市场的成长。

老年人口增加

全球老年人口的增加，加上慢性病盛行率的上升，正在推动预测期内市场的成长。值得注意的是，2019年，60岁及以上人口在人口中的数量和比例达到10亿，预计到2030年，这一数字将增至14亿，到2050年将增至21亿。此外，报销政策的完善预计经济将有助于市场的扩张。此外，全球患者人数的成长和医疗基础设施的进步将推动市场。

此外，全球癌症发生率不断上升是推动市场成长的重要因素。根据世界卫生组织统计，2020年约有1,000万人死于癌症。值得注意的是，肺癌死亡人数最多，达180万人，其次是结肠癌和直肠癌（91.6万人死亡）、肝癌（83万人类死亡） ）、胃癌（769,000 人死亡）和乳癌（685,000 人死亡）。此外，据观察，低收入和中低收入国家约 30% 的癌症病例是由人类乳突病毒 (HPV) 和肝炎等致癌物质引起的。此外，增加对研发活动的投资以开发更有效的医疗解决方案，再加上新产品的推出，预计将在整个预测期内推动全球化疗市场的成长。

增加研发活动

研发工作的重点是确定癌细胞中可用于治疗的特定分子标靶。标靶治疗旨在攻击癌细胞，同时最大限度地减少对健康细胞的损害，减少副作用并提高治疗效果。基因组学和分子分析的进步使得能够开发针对个别患者的基因组成和癌症特征的个人化化疗方案。这种方法提高了治疗精确度并增加了积极反应的可能性。研发导致了具有不同作用机制的新化疗药物的发现和开发。这些药物可能具有提高疗效、降低毒性和对抗抗药性的新方法。研究人员正在探索化疗药物与其他治疗方法的组合，例如免疫疗法、标靶疗法和放射疗法。这些组合可以增强整体治疗效果并克服抗药性。创新的药物传递系统，包括奈米颗粒、脂质体和植入物，可改善化疗药物的药物动力学和生物利用度，提高其有效性并减少副作用。研发旨在了解抗药性机制并制定克服抗药性的策略，从而延长化疗的有效性。研究人员致力于开发副作用越来越少的化疗药物，从而改善患者在治疗期间的生活品质。

主要市场挑战

治疗费用高

化疗药物的高成本对市场的成长构成了重大障碍。高额化疗费用可能会给患者带来经济障碍，导致治疗延迟或延迟、不遵守规定的治疗方案以及治疗效果降低。经济资源有限的患者可能在接受化疗方面面临差异，加剧现有的医疗保健不平等。高成本会影响患者的治疗决策，可能导致基于财务考量而不是医疗必要性的次优选择。化疗的经济压力可能会导致治疗机会减少，特别是对于没有保险或保险不足的患者。此外，发展中经济体缺乏熟练专业人员和医疗基础设施不足，为化疗药物市场带来了挑战。此外，这些药物的副作用，包括心臟问题、红血球计数减少、疲劳、体重减轻、脱髮、腹泻、肺、肾和肝功能下降、骨密度下降以及公众认识有限，限制并进一步阻碍2018-2028 年预测期内市场的成长。

治疗对健康的不良影响

化疗通常会带来一系列副作用，包括噁心、呕吐、疲劳、脱髮、疼痛和认知改变。这些副作用会显着降低患者的生活品质并导致身体和情绪困扰。出现严重副作用的前景可能会导致一些患者避免或延迟化疗治疗。不依从可能会影响治疗效果并阻碍正面的结果。一些化疗药物可能会产生潜在的长期健康后果，例如器官损伤或继发性癌症，这可能会影响患者接受治疗的意愿。

主要市场趋势

创新技术开发

化疗在延长癌症患者的寿命方面发挥了关键作用，比他们的预期生存期多了几年。化疗领域的最新突破涉及使用专门设计的含有抗癌药物的奈米颗粒，它可以选择性地针对受影响的区域，同时保护健康细胞。这种创新方法在根除恶性细胞同时保护周围健康组织方面表现出显着的功效。透过利用光子雷射器，医疗专业人员能够精确监测这些载药奈米颗粒在患者体内的释放、持续时间和分布。令人兴奋的是，加州大学洛杉矶分校目前正在进行一项临床试验，以评估这种方法的有效性，该方法在治疗早期癌症患者方面显示出有希望的结果。随着即将进入化疗市场，这项突破性技术在改变癌症治疗方面具有巨大潜力。

研发活动数量的增加

化疗药物市场的成长是由研发活动的增加所推动的，为市场扩张提供了有利的机会。研究计划的重点是确定化疗药物的新化合物、分子和作用机制。新药的发现扩大了可用治疗选择的范围，并解决了未满足的医疗需求。研发旨在开发标靶化疗药物，专门攻击癌细胞，同时最大限度地减少对健康细胞的伤害。这些疗法可提高疗效并减少副作用。研究探讨了化疗药物与免疫疗法或标靶治疗等其他治疗方式结合的协同效应，从而产生更全面、更有效的癌症治疗方案。研发工作确定了可以预测患者对特定化疗药物反应的生物标记物，从而实现个人化治疗选择并改善治疗结果。持续的研究导致优化药物配方的开发，包括缓释配方、奈米颗粒和脂质体，从而增强药物传输、生物利用度和患者依从性。此外，预测期内新兴市场数量的增加和新产品的推出将进一步促进化疗药物市场成长的积极前景。

细分市场洞察

类型洞察

化疗市场依药物类别细分，包括烷化剂、抗代谢物、抗肿瘤抗生素、荷尔蒙、单株抗体等。烷化剂领域目前在市场上占据主导地位。已知烷基化物质会导致 DNA 链断裂、奇数碱基配对或 DNA 链交联，最终阻碍细胞分裂。此外，烷基化化学物质通常被认为是细胞週期非特异性的，因为它们能够在细胞週期的不同点消除细胞。随着全球癌症发生率持续上升，抗代谢药物市场预计将大幅扩张。此外，抗代谢药物产业的成长也可归因于管道研究的增加和医疗保健成本的不断上升。

管理途径见解

口服类别是市场上最大的贡献者，预计在整个预测期内将出现显着扩张。口腔癌治疗药物有丸剂、胶囊或液体形式。在家中，减少频繁前往医疗机构进行静脉输液的需要。这对于居住在远离治疗中心的患者尤其有益。在家服用化疗药物的能力可以为患者带来更好的生活质量，因为他们对治疗计划有更大的灵活性和控制力。与静脉注射治疗相比，口服化疗可能有助于减少住院时间和相关费用，从而节省潜在的医疗费用。口服化疗可最大限度地减少对患者日常生活和活动的干扰，使他们能够继续工作、与家人共度时光以及从事其他正常活动。然而，静脉注射途径的成长速度最快。由于以静脉注射给药，化疗药物比口服和局部治疗药物起效更快，因为它们能迅速吸收到血液中。

区域洞察

在多家化疗药物製造商和医疗支出增加的推动下，北美化疗市场有望主导该产业。医疗设施的便利性以及尖端技术在癌症研究和治疗中的应用进一步促进了其成长。

欧洲化疗市场占据第二大市场份额，这得益于新癌症疗法的监管审批便利性、癌症发病率上升以及市场上主要公司的大量研发投资。值得注意的是，德国化疗市场拥有最大的市场份额，而英国化疗市场在欧洲地区的成长率最高。

预计 2023 年至 2028 年，亚太化疗市场将快速扩张。这可归因于该地区政府的意识措施和不断上升的医疗成本。训练有素的医疗保健提供者的可用性和对化疗药物的需求不断增加，加上仿製药的可及性不断扩大，预计将减缓市场的成长率。此外，中国化疗市场占有最大的市场份额，印度化疗市场在亚太地区成长最高。

主要市场参与者

  • F.霍夫曼-拉罗氏有限公司
  • 迈兰公司
  • 梯瓦製药工业股份有限公司
  • 赛诺菲
  • 辉瑞公司
  • 葛兰素史克公司
  • 诺华公司
  • 拜耳公司
  • 礼来公司
  • 默克公司

报告范围：

化疗市场，依类型：

  • 烷基化剂
  • 抗代谢药
  • 抗肿瘤抗生素
  • 荷尔蒙
  • 单株抗体
  • 其他的

化疗市场，依适应症分类：

  • 肿瘤学/癌症
  • 骨髓疾病
  • 免疫系统疾病
  • 其他的

化疗市场，按剂型：

  • 胶囊
  • 平板电脑
  • 注射
  • 其他的

化疗市场，依给药途径划分：

  • 口服
  • 注射用
  • 其他的

化疗市场，依最终用户划分：

  • 医院
  • 专科诊所
  • 其他的

化疗市场（按地区）：

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 法国
    • 英国
    • 义大利
    • 德国
    • 西班牙
  • 亚太
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 韩国
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥伦比亚
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 科威特
    • 土耳其
    • 埃及

竞争格局

公司概况：全球化疗市场主要公司的详细分析。

可用的客製化：

全球化疗市场报告以及给定的市场资料，技术科学研究根据公司的具体需求提供客製化服务。该报告可以使用以下自订选项：

公司资讯

  • 其他市场参与者（最多五个）的详细分析和概况分析。

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球化疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型（烷化剂、抗代谢物、抗肿瘤抗生素、荷尔蒙、单株抗体、其他）
    • 按适应症（肿瘤/癌症、骨髓疾病、免疫系统疾病、其他）
    • 按剂型（胶囊、锭剂、注射剂、其他）
    • 依给药途径（口服、肠胃外、其他）
    • 按最终使用者（医院、专科诊所、其他）
    • 按地区
    • 按公司划分 (2022)
  • 市场地图

第 6 章：北美化疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按指示
    • 依剂型分类
    • 依给药途径
    • 由最终用户
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章：欧洲化疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按指示
    • 依剂型分类
    • 依给药途径
    • 由最终用户
    • 按国家/地区
  • 欧洲：国家分析
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙

第 8 章：亚太化疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按指示
    • 依剂型分类
    • 依给药途径
    • 由最终用户
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第 9 章：南美洲化疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按指示
    • 依剂型分类
    • 依给药途径
    • 由最终用户
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲化疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按指示
    • 依剂型分类
    • 依给药途径
    • 由最终用户
    • 按国家/地区
  • MEA：国家分析
    • 南非化疗
    • 沙乌地阿拉伯化疗
    • 阿联酋化疗

第 11 章：市场动态

第 12 章：市场趋势与发展

第 13 章：全球化疗市场：SWOT 分析

第14章：竞争格局

  • 商业概览
  • 应用程式产品
  • 最近的发展
  • 主要人员
  • SWOT分析
    • F. Hoffmann-La Roche Ltd.
    • Mylan NV
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Novartis AG
    • Bayer AG
    • Eli Lilly and Company
    • Merck & Co., Inc.

第 15 章：策略建议

第 16 章：关于我们与免责声明

简介目录
Product Code: 4735

The global Chemotherapy Market was valued at USD 8.26 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 8.51% through 2028. Cancer, as stated by the World Health Organization (WHO), is the second leading cause of mortality worldwide, resulting in an estimated 9.6 million deaths in 2018. Given the rising cancer rates, there will be an increased demand for chemotherapy medications. Chemotherapy is a cancer treatment approach that utilizes potent chemicals to target and eliminate rapidly dividing cells within the body. It has proven efficacy in reducing cancer cell count, impeding cancer progression, and shrinking tumors.

Chemotherapy, often administered alone or in combination, is a versatile treatment modality for a wide range of cancers. It serves as a primary or sole treatment, eliminating hidden cancer cells and preparing patients for other interventions such as radiation or surgery. Additionally, it can be employed to alleviate cancer-related signs and symptoms by selectively targeting cancer cells.

Key Market Drivers

Market Overview
Forecast Period2024-2028
Market Size 2022USD 8.26 Billion
Market Size 2028USD 13.39 Billion
CAGR 2023-20288.51%
Fastest Growing SegmentAlkylating Agents
Largest MarketNorth America

Rising Incidences of Cancers

The increasing prevalence of cancer is projected to drive the growth rate of the chemotherapy drug market. According to the World Health Organization (WHO), cancer is the leading cause of mortality worldwide, accounting for approximately 10 million deaths in 2020, or nearly one in every six deaths. Each year, around 400,000 children receive a cancer diagnosis. Cervical cancer ranks as the most common cancer in 23 countries across the globe. Chemotherapy, often used in conjunction with other cancer treatments, remains the predominant approach to cancer treatment. Neo-adjuvant chemotherapy refers to chemotherapy administered prior to surgery and radiation therapy to reduce tumor size, while adjuvant chemotherapy is administered after surgery or radiation therapy to further shrink the tumor.

Increasing Investment in Healthcare Infrastructure

Another significant factor impacting the growth rate of the chemotherapy drug market is the increasing healthcare expenditure, which contributes to the improvement of its infrastructure. Moreover, various government organizations are committed to enhancing healthcare infrastructure through increased funding, thereby influencing market dynamics. Increased investment allows for the establishment and expansion of specialized cancer treatment centers equipped with state-of-the-art facilities for chemotherapy administration, monitoring, and supportive care. Healthcare infrastructure investment ensures that patients have access to oncologists, hematologists, pathologists, radiologists, and other specialists who play critical roles in planning and delivering chemotherapy treatments. Well-equipped healthcare facilities can provide accurate and timely cancer diagnoses through advanced imaging technologies, biopsies, and molecular testing, guiding the selection of appropriate chemotherapy regimens. Adequate infrastructure supports the conduct of clinical trials, allowing patients to access innovative chemotherapy treatments and contributing to the development of new therapeutic options. Furthermore, the expanding geriatric population and the growing demand for advanced cancer drugs will drive the expansion of the chemotherapy drug market. Additionally, the growing awareness of chemotherapy, coupled with the rising number of patients undergoing chemotherapy and radiotherapy treatments, is expected to augment the market's growth.

Increasing Geriatric Population

The increase in the geriatric population worldwide, coupled with a rising prevalence of chronic diseases, is driving the market's growth during the forecast period. It is worth noting that the number and proportion of individuals aged 60 years and older in the population reached 1 billion in 2019, and this figure is projected to rise to 1.4 billion by 2030 and 2.1 billion by 2050. Moreover, improved reimbursement policies in advanced economies are expected to contribute to the market's expansion. Additionally, the market will be propelled by the growing patient population globally and advancements in healthcare infrastructure.

Furthermore, the escalating incidence of cancer worldwide is a significant factor driving market growth. According to the World Health Organization, approximately 10 million people succumbed to cancer in 2020. Notably, lung cancer accounted for the highest number of deaths, with 1.80 million fatalities, followed by colon and rectum cancer (916,000 deaths), liver cancer (830,000 deaths), stomach cancer (769,000 deaths), and breast cancer (685,000 deaths). Additionally, it has been observed that about 30% of cancer cases in low and lower-middle-income countries are caused by cancer-causing agents such as the human papillomavirus (HPV) and hepatitis. Moreover, increased investments in research and development activities to develop more effective medical solutions, coupled with the launch of new products, are expected to drive the growth of the global chemotherapy market throughout the forecast period.

Increasing Research & Development Activities

R&D efforts are focused on identifying specific molecular targets in cancer cells that can be exploited for treatment. Targeted therapies aim to attack cancer cells while minimizing damage to healthy cells, reducing side effects, and improving treatment efficacy. Advancements in genomics and molecular profiling enable the development of personalized chemotherapy regimens tailored to an individual patient's genetic makeup and cancer characteristics. This approach enhances treatment precision and increases the likelihood of positive responses. R&D leads to the discovery and development of new chemotherapy drugs with different mechanisms of action. These drugs may have improved efficacy, reduced toxicity, and novel ways of combating drug resistance. Researchers are exploring combinations of chemotherapy agents with other treatments, such as immunotherapy, targeted therapy, and radiation therapy. These combinations can enhance the overall therapeutic effect and overcome resistance. Innovative drug delivery systems, including nanoparticles, liposomes, and implants, improve the pharmacokinetics and bioavailability of chemotherapy drugs, enhancing their effectiveness and reducing side effects. R&D aims to understand the mechanisms of drug resistance and develop strategies to overcome it, allowing for the prolonged effectiveness of chemotherapy treatments. Researchers work on developing chemotherapy agents that have fewer and less severe side effects, improving patients' quality of life during treatment.

Key Market Challenges

High Cost of Treatment

The high cost associated with chemotherapy drugs poses a significant obstacle to the growth of the market. High chemotherapy costs can create financial barriers for patients, leading to delayed or deferred treatment, non-adherence to prescribed regimens, and reduced treatment effectiveness. Patients with limited financial resources may face disparities in accessing chemotherapy treatments, exacerbating existing healthcare inequalities. High costs can influence patients' treatment decisions, potentially leading to suboptimal choices based on financial considerations rather than medical necessity. The financial strain of chemotherapy can lead to reduced treatment access, particularly for uninsured or underinsured patients. Moreover, the shortage of skilled professionals and inadequate healthcare infrastructure in developing economies present challenges to the chemotherapy drug market. Additionally, the side effects of these drugs, including heart problems, decreased red blood cell count, fatigue, weight loss, hair loss, diarrhea, reduced lung, kidney, and liver function, decreased bone density, and limited awareness among the public, act as restraints and further hinder the market's growth during the forecast period of 2018-2028.

Adverse Health Effects by Treatment

Chemotherapy is often associated with a range of side effects, including nausea, vomiting, fatigue, hair loss, pain, and cognitive changes. These side effects can significantly diminish patients' quality of life and lead to physical and emotional distress. The prospect of experiencing severe side effects may lead some patients to avoid or delay chemotherapy treatment. Non-adherence can compromise treatment efficacy and hinder positive outcomes. Some chemotherapy drugs may have potential long-term health consequences, such as organ damage or secondary cancers, which can impact patients' willingness to undergo treatment.

Key Market Trends

Development of Innovative Technology

Chemotherapy has played a pivotal role in extending the lifespan of cancer patients, surpassing their expected survival by several years. The latest breakthrough in the field of chemotherapy involves the administration of specially designed nanoparticles containing cancer-fighting medications, which selectively target affected areas while sparing healthy cells. This innovative approach has demonstrated remarkable efficacy in eradicating malignant cells while preserving surrounding healthy tissue. By utilizing photon lasers, medical professionals are able to precisely monitor the release, duration, and distribution of these medication-loaded nanoparticles within the patient's body. Excitingly, the University of California, Los Angeles, is currently conducting a clinical trial to evaluate the effectiveness of this approach, which has shown promising outcomes in the treatment of early-stage cancer patients. With its imminent entry into the chemotherapeutic market, this groundbreaking technique holds great potential for transforming cancer treatment.

Increase in the Number of Research and Development Activities

The growth of the chemotherapy drug market is driven by a rise in research and development activities, presenting advantageous opportunities for market expansion. Research initiatives focus on identifying new compounds, molecules, and mechanisms of action for chemotherapy drugs. The discovery of novel drugs expands the range of available treatment options and addresses unmet medical needs. R&D aims to develop targeted chemotherapy drugs that specifically attack cancer cells while minimizing harm to healthy cells. These therapies offer enhanced efficacy and reduced side effects. Research explores the synergistic effects of combining chemotherapy drugs with other treatment modalities, such as immunotherapy or targeted therapy, leading to more comprehensive and effective cancer treatment regimens. R&D efforts identify biomarkers that can predict patient responses to specific chemotherapy drugs, enabling personalized treatment selection and improving treatment outcomes. Ongoing research leads to the development of optimized drug formulations, including extended-release formulations, nanoparticles, and liposomes, enhancing drug delivery, bioavailability, and patient compliance. Additionally, the increasing number of emerging markets and new product launches during the forecast period will further contribute to the positive prospects for the growth of the chemotherapy drug market.

Segmental Insights

Type Insights

The chemotherapy market is segmented based on drug class, including Alkylating Agents, Anti-metabolites, Anti-Tumor Antibiotics, Hormones, Monoclonal Antibodies, and Others. The alkylating agent segment currently holds the dominant position in the market. Alkylating substances are known to cause DNA strand breakage, odd base pairing, or cross-linking of DNA strands, which ultimately obstruct cell division. Moreover, alkylating chemicals are generally regarded as cell cycle phase nonspecific, as they have the ability to eliminate cells at various points in the cell cycle. As cancer rates continue to rise globally, the market for anti-metabolite drugs is projected to witness significant expansion. Additionally, the growth of the anti-metabolite medication sector can also be attributed to increased pipeline research and the escalating healthcare costs.

Route of Administration Insights

The oral category, being the largest contributor in the market, is expected to demonstrate significant expansion throughout the projected period. An oral cancer treatment medication is available in the form of pills, capsules, or liquids. home, reducing the need for frequent visits to healthcare facilities for IV infusions. This can be particularly beneficial for patients who live far from treatment centers. The ability to take chemotherapy drugs at home can lead to a better quality of life for patients, as they have more flexibility and control over their treatment schedule. Oral chemotherapy may help reduce the need for hospital stays and associated costs compared to intravenous treatments, resulting in potential healthcare cost savings. Oral chemotherapy minimizes the disruption of patients' daily routines and activities, allowing them to continue working, spending time with family, and engaging in other normal activities. However, the intravenous route has exhibited the most rapid growth rate. Due to their intravenous administration, chemotherapy drugs act more swiftly compared to oral and topical treatments, as they are rapidly absorbed into the bloodstream.

Regional Insights

The North American chemotherapy market is poised to dominate the industry, driven by multiple manufacturers of chemotherapy drugs and increased healthcare spending. Accessibility to medical facilities and the application of cutting-edge technology in cancer research and treatment further contribute to its growth.

Europe's chemotherapy market holds the second-largest market share, fueled by the ease of regulatory approval for novel cancer therapies, rising cancer incidence, and significant R&D investments by major companies in the market. Notably, the German chemotherapy market boasts the largest market share, while the UK chemotherapy market exhibits the highest growth rate in the European region.

The Asia-Pacific Chemotherapy Market is projected to experience rapid expansion from 2023 to 2028. This can be attributed to government awareness initiatives and escalating healthcare costs in the region. The availability of trained healthcare providers and the increasing demand for chemotherapy drugs, coupled with the expanding accessibility of generic medications, are expected to moderate the market's growth rate. Additionally, China's chemotherapy market commands the largest market share, and the Indian chemotherapy market demonstrates the highest growth rate in the Asia-Pacific region.

Key Market Players

  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Bayer AG
  • Eli Lilly and Company
  • Merck & Co., Inc.

Report Scope:

In this report, the Global Chemotherapy Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Chemotherapy Market, By Type:

  • Alkylating Agents
  • Anti-metabolites
  • Anti-Tumor Antibiotics
  • Hormones
  • Monoclonal Antibodies
  • Others

Chemotherapy Market, By Indication:

  • Oncology/Cancer
  • Bone Marrow Diseases
  • Immune System Disorders
  • Others

Chemotherapy Market, By Dosage Form:

  • Capsule
  • Tablets
  • Injections
  • Others

Chemotherapy Market, By Route of Administration:

  • Oral
  • Parenteral
  • Others

Chemotherapy Market, By End User:

  • Hospitals
  • Specialty Clinics
  • Others

Chemotherapy Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chemotherapy Market.

Available Customizations:

Global Chemotherapy market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Chemotherapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Alkylating Agents, Anti-metabolites, Anti-Tumor Antibiotics, Hormones, Monoclonal Antibodies, Others)
    • 5.2.2. By Indication (Oncology/Cancer, Bone Marrow Diseases, Immune System Disorders, Others)
    • 5.2.3. By Dosage Form (Capsule, Tablets, Injections, Others)
    • 5.2.4. By Route of Administration (Oral, Parenteral, Others)
    • 5.2.5. By End User (Hospitals, Specialty Clinics, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2022)
  • 5.3. Market Map

6. North America Chemotherapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Indication
    • 6.2.3. By Dosage Form
    • 6.2.4. By Route of Administration
    • 6.2.5. By End Users
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Chemotherapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By Dosage Form
        • 6.3.1.2.4. By Route of Administration
        • 6.3.1.2.5. By End Users
    • 6.3.2. Canada Chemotherapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By Dosage Form
        • 6.3.2.2.4. By Route of Administration
        • 6.3.2.2.5. By End Users
    • 6.3.3. Mexico Chemotherapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By Dosage Form
        • 6.3.3.2.4. By Route of Administration
        • 6.3.3.2.5. By End Users

7. Europe Chemotherapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Indication
    • 7.2.3. By Dosage Form
    • 7.2.4. By Route of Administration
    • 7.2.5. By End Users
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Chemotherapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By Dosage Form
        • 7.3.1.2.4. By Route of Administration
        • 7.3.1.2.5. By End Users
    • 7.3.2. United Kingdom Chemotherapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By Dosage Form
        • 7.3.2.2.4. By Route of Administration
        • 7.3.2.2.5. By End Users
    • 7.3.3. Italy Chemotherapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By Dosage Form
        • 7.3.3.2.4. By Route of Administration
        • 7.3.3.2.5. By End Users
    • 7.3.4. France Chemotherapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Indication
        • 7.3.4.2.3. By Dosage Form
        • 7.3.4.2.4. By Route of Administration
        • 7.3.4.2.5. By End Users
    • 7.3.5. Spain Chemotherapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Indication
        • 7.3.5.2.3. By Dosage Form
        • 7.3.5.2.4. By Route of Administration
        • 7.3.5.2.5. By End Users

8. Asia-Pacific Chemotherapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Indication
    • 8.2.3. By Dosage Form
    • 8.2.4. By Route of Administration
    • 8.2.5. By End Users
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Chemotherapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By Dosage Form
        • 8.3.1.2.4. By Route of Administration
        • 8.3.1.2.5. By End Users
    • 8.3.2. India Chemotherapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By Dosage Form
        • 8.3.2.2.4. By Route of Administration
        • 8.3.2.2.5. By End Users
    • 8.3.3. Japan Chemotherapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By Dosage Form
        • 8.3.3.2.4. By Route of Administration
        • 8.3.3.2.5. By End Users
    • 8.3.4. South Korea Chemotherapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By Dosage Form
        • 8.3.4.2.4. By Route of Administration
        • 8.3.4.2.5. By End Users
    • 8.3.5. Australia Chemotherapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By Dosage Form
        • 8.3.5.2.4. By Route of Administration
        • 8.3.5.2.5. By End Users

9. South America Chemotherapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Indication
    • 9.2.3. By Dosage Form
    • 9.2.4. By Route of Administration
    • 9.2.5. By End Users
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Chemotherapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By Dosage Form
        • 9.3.1.2.4. By Route of Administration
        • 9.3.1.2.5. By End Users
    • 9.3.2. Argentina Chemotherapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By Dosage Form
        • 9.3.2.2.4. By Route of Administration
        • 9.3.2.2.5. By End Users
    • 9.3.3. Colombia Chemotherapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By Dosage Form
        • 9.3.3.2.4. By Route of Administration
        • 9.3.3.2.5. By End Users

10. Middle East and Africa Chemotherapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Indication
    • 10.2.3. By Dosage Form
    • 10.2.4. By Route of Administration
    • 10.2.5. By End Users
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Chemotherapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By Dosage Form
        • 10.3.1.2.4. By Route of Administration
        • 10.3.1.2.5. By End Users
    • 10.3.2. Saudi Arabia Chemotherapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By Dosage Form
        • 10.3.2.2.4. By Route of Administration
        • 10.3.2.2.5. By End Users
    • 10.3.3. UAE Chemotherapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By Dosage Form
        • 10.3.3.2.4. By Route of Administration
        • 10.3.3.2.5. By End Users

11. Market Dynamics

12. Market Trends & Developments

13. Global Chemotherapy Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Application Offerings
  • 14.3. Recent Developments
  • 14.4. Key Personnel
  • 14.5. SWOT Analysis
    • 14.5.1. F. Hoffmann-La Roche Ltd.
    • 14.5.2. Mylan N.V.
    • 14.5.3. Teva Pharmaceutical Industries Ltd.
    • 14.5.4. Sanofi
    • 14.5.5. Pfizer Inc.
    • 14.5.6. GlaxoSmithKline plc
    • 14.5.7. Novartis AG
    • 14.5.8. Bayer AG
    • 14.5.9. Eli Lilly and Company
    • 14.5.10. Merck & Co., Inc.

15. Strategic Recommendations

16. About Us & Disclaimer